|
|
|
gabapentinoids (GABA analogues), addiction/physical dependence and withdrawal |
|
|
|
Gambling disorder |
|
|
|
Gastrointestinal disorders, drug safety in older patients/dementia |
|
Gastrointestinal hypomotility, clozapine-induced |
|
Gastrointestinal necrosis |
|
General Guidelines |
|
|
|
Generalised seizures, severe alcohol withdrawal |
|
General recommendations for prescribing intramuscular clozapine |
|
Genetic testing for clozapine treatment |
|
|
|
genitourinary symptoms of menopause (GSM) 857 |
|
|
|
glomerular filtration rate (GFR), estimation for renal impairment assessment |
|
|
|
Glucose homeostasis effects |
|
|
|
Glucose tolerance impairment association |
|
|
|
|
|
Gonadotrophin-releasing hormone agonists, medical menopause induction test |
|
gynaecological and obstetric haemorrhage, SSRI risks |
|
Galactorrhea |
|
gamma-glutamyl transferase (GGT), psychotropic agent effects |
|
gastrointestinal bleeding, SSRI risks |
|
Gastrointestinal disturbances, antiretrovirals |
|
Gastrointestinal irritant drugs, increased risk of bleeding in hepatic impairment |
